TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06293716
Drug: CVL237 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Study: NCT06293716
Drug: CVL237 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Study: NCT06718309
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
Study: NCT06718309
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
Study: NCT06718998
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
Study: NCT05807412
Drug: PrabotulinumtoxinA-Xvfs
Normalized name: prabotulinumtoxinA-xvfs
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim.
Study: NCT06123715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
Study: NCT06543459
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
Study: NCT06543459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
Study: NCT05985655
Drug: GTAEXS617
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTAEXS617 tablets daily
Study: NCT02497222
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02497222
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03481842
Drug: BIBW2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: in a minimally sufficient therapeutic dose
Study: NCT05103215
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
Study: NCT05896553
Drug: intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intranasal Placebo
Study: NCT03068247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 week treatment
Study: NCT05837416
Drug: blue®m Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
Study: NCT05837416
Drug: NBF GINGIVAL GEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
Study: NCT05837416
Drug: COE-PAK™
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
Study: NCT05337592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04325958
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg cigarette of plant material
Study: NCT04777006
Drug: Antidepressant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care.
Study: NCT05850819
Drug: Sterile gauze pack
Normalized name: GAUZE,STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction socket allowed to heal without augmentation with any material
Study: NCT05487742
Drug: placebo salin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: salin infused as aplacebo for 72 hours
Study: NCT05305872
Drug: Gandouling
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
Study: NCT05135039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100mg/day/patient
Study: NCT05708573
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
Study: NCT05708573
Drug: ALXN2040
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
Study: NCT01882712
Drug: CD07805/47 Gel 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01882712
Drug: CD07805/47 Gel Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05046873
Drug: NNC0480-0389 A 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Study: NCT05792163
Drug: SNP318 (A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT05792163
Drug: Placebo (B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching the SNP318 capsules
Study: NCT04855240
Drug: ACP-044 Dose A
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose of ACP-044 Dose A
Study: NCT04855240
Drug: ACP-044 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of ACP-044 Dose B
Study: NCT04855240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of placebo
Study: NCT05348681
Drug: RIST4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Study: NCT05348681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04901663
Drug: Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally twice daily for 2 weeks
Study: NCT06632613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study: NCT04767061
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Study: NCT06632600
Drug: LXE408
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXE408 administered by oral route
Study: NCT06036576
Drug: Levothyroxine Pill
Normalized name: levothyroxine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
Study: NCT06632600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by oral route
Study: NCT06523504
Drug: The 0.02% ATP Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: wear SP, and use 0.02%ATP eye drops, once nightly, both eye
Study: NCT06523504
Drug: The 0.04% ATP Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: wear SP, and use 0.04%ATP eye drops, once nightly, both eye
Study: NCT05860907
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g each time, three times a day
Study: NCT05802420
Drug: Later-line therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study: NCT06112379
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion Experimental/Active Comparator
Study: NCT04790006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06112379
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion Experimental/Active Comparator
Study: NCT06112379
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet Oral route of administration Experimental/Active Comparator
Study: NCT04877379
Drug: VNRX-7145
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactamase inhibitor
Study: NCT04877379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05623267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Sugemalimab
Study: NCT04915755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered
Study: NCT00000954
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06293885
Drug: Dextrose 50
Normalized name: DEXTROSE 50% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: a solution of 50% glucose (D50) will be injected into your pleural space
Study: NCT04727229
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Normal Saline near the stellate ganglion
Study: NCT06671483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zasocitinib or active comparator matching placebo.
Study: NCT05055609
Drug: TRE-515
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
Study: NCT04778189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
Study: NCT04778189
Drug: i.v dexmethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
Study: NCT04723940
Drug: Doxycycline Hcl
Normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline HCl will given for 6 weeks to treat joint infection
Study: NCT04723940
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin will given for 6 weeks to treat joint infection
Study: NCT06181838
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
Study: NCT04540289
Drug: Optimal Medical Therapy (OMT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure
Study: NCT05133518
Drug: MELT-300
Normalized name: Feldene Melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet
Study: NCT05133518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet
Study: NCT05079802
Drug: Double antibiotic paste mixed with propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
Study: NCT06039423
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional general anaesthesia receiving multimodal analgesia
Study: NCT05070312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000751
Drug: Anti-HIV Immune Serum Globulin (Human)
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000751
Drug: Globulin, Immune
Normalized name: globulin, immune
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04821206
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Initiation of a DMARDs
Study: NCT04821206
Drug: JAK Inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Initiation of a JAK Inhibitor
Study: NCT06061393
Drug: Venofer 200 MG Per 10 ML Injection
Normalized name: Venofer 200 MG per 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: treat anemia with venofer up to 5 doses
Study: NCT05597540
Drug: Usual antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
Study: NCT05980065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
Study: NCT06112028
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
Study: NCT04757571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus standard therapy
Study: NCT05509699
Drug: Anti-PD-1/L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
Study: NCT04707261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo 10 mg once daily
Study: NCT05263570
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Study: NCT05275647
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
Study: NCT05978349
Drug: adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Study: NCT05125328
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
Study: NCT05947201
Drug: Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
Study: NCT04891900
Drug: TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle
Study: NCT05270954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
Study: NCT04713826
Drug: BAY2586116
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 µg, nasal spray administration.
Study: NCT04713826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BAY2586116, nasal spray administration.
Study: NCT06328153
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
Study: NCT05767632
Drug: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Study: NCT05767632
Drug: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Study: NCT04147065
Drug: Duration of eradication regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day eradication regimen
Study: NCT04611763
Drug: Flurbiprofen axetil preoperatively
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: give Flurbiprofen axetil 15 min before surgery
Study: NCT04611763
Drug: Flurbiprofen axetil postoperatively
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: give Flurbiprofen axetil at the end of surgery
Study: NCT04779255
Drug: Procedure (Tumesent anesthesia)
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
Study: NCT05608044
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib or trifluridine and tipiracil.
Study: NCT04843709
Drug: MRG004A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT04822818
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Study: NCT06353152
Drug: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-/multiple-dose infusion
Study: NCT05350215
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
Study: NCT04719481
Drug: Pravastatin Sodium 80 MG
Normalized name: pravastatin sodium 80 MG
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily oral administration of 80mg
Study: NCT04719481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administration
Study: NCT05559905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to molnupiravir taken twice daily by mouth.